ADC Therapeutics SA announced that, on December 15, 2022, Robert A. Schmidt informed the Company of his resignation as the Company's Chief Accounting Officer, effective December 30, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.65 USD | -1.49% |
|
-19.70% | +59.64% |
May. 30 | Cantor Fitzgerald Initiates ADC Therapeutics at Overweight Rating | MT |
May. 07 | HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+59.64% | 255M | |
+15.19% | 121B | |
+19.91% | 114B | |
+8.24% | 23.61B | |
-19.80% | 20.43B | |
-16.19% | 16.55B | |
-13.45% | 16.45B | |
-44.35% | 15.59B | |
+2.13% | 13.54B | |
+66.67% | 15.19B |
- Stock Market
- Equities
- ADCT Stock
- News ADC Therapeutics SA
- ADC Therapeutics SA Announces Resignation of Robert A. Schmidt as Company’S Chief Accounting Officer, Effective December 30, 2022